Treatment Outcome of Axitinib for Metastatic Renal-Cell Carcinoma Patients
Axitinib was approved for use in Japan as a salvage therapy for patients with metastatic renal cell carcinoma (RCC) in 2012. We retrospectively evaluated the cases of 32 RCC patients that were treated with Axitinib as a 2nd- or further-line therapy between November 2012 and March 2017. Overall survi...
Ausführliche Beschreibung
Bibliographische Detailangaben
| Veröffentlicht in: | Hinyokika kiyo. Acta urologica Japonica. - 1962. - 64(2018), 9 vom: 14. Sept., Seite 353-358
|
|---|
| 1. Verfasser: |
Kusakabe, Naohisa
(VerfasserIn) |
|---|
| Weitere Verfasser: |
Osawa, Takahiro,
Miyata, Haruka,
Kikuchi, Hiroshi,
Matsumoto, Ryuji,
Maruyama, Satoru,
Abe, Takashige,
Shinohara, Nobuo |
|---|
| Format: | Online-Aufsatz
|
|---|
| Sprache: | Japanese |
|---|
| Veröffentlicht: |
2018
|
|---|
| Zugriff auf das übergeordnete Werk: | Hinyokika kiyo. Acta urologica Japonica
|
|---|
| Schlagworte: | Journal Article
Antineoplastic Agents
Axitinib
C9LVQ0YUXG |
|---|